<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39557283</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Assessing the Impact of SARS-CoV-2 on Influenza-Like Illness Surveillance Trends in the Community during the 2023/2024 Winter in England.</ArticleTitle><Pagination><StartPage>107307</StartPage><MedlinePgn>107307</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2024.107307</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(24)00383-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Influenza-like-illness is a commonly used symptom categorisation in seasonal disease surveillance focusing on influenza in community and clinical settings. However, SARS-CoV-2 often causes presentation with a similar symptom profile. We explore how SARS-CoV-2 positive individuals can influence surveillance trends for WHO, CDC and ECDC influenza-like-illness criteria.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Harnessing the Winter COVID-19 Infection Study in England, a cohort study, the prevalence of different influenza-like-illness definitions are modelled using multilevel-regression and poststratification using age and spatial stratifications with temporal smoothing. Trends over time across stratifications were compared for SARS-CoV-2 positive and negative individuals to understand differences in influenza-like-illness trends. Symptom presentation across positive and negative SARS-CoV-2 cases were compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">SARS-CoV-2 symptom profiles are shown to overlap with the influenza-like-illness case definitions, particularly for "cough" and "fever", causing SARS-CoV-2 positive individuals to be frequently detected as influenza-like-illness cases. The trend of SARS-CoV-2 positives is a substantial component of the influenza-like-illness modelled trend driving an earlier perceived peak in prevalence. The ECDC symptom definition was most influenced by SARS-CoV-2 positive individuals.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Using a large community cohort we show how SARS-CoV-2 can impact influenza-like-illness surveillance trends. SARS-CoV-2 makes up a substantial part of the community influenza-like-illness burden and public health messaging should reflect this when discussing influenza-like-illness. We show influenza-like-illness is no longer a strong proxy for influenza activity alone.</AbstractText><CopyrightInformation>Copyright Â© 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mellor</LastName><ForeName>Jonathon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UK Health Security Agency, 10 South Colonnade, Poplar, London, UK. Electronic address: Jonathon.mellor@ukhsa.gov.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fyles</LastName><ForeName>Martyn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UK Health Security Agency, 10 South Colonnade, Poplar, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paton</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>UK Health Security Agency, 10 South Colonnade, Poplar, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UK Health Security Agency, 10 South Colonnade, Poplar, London, UK; Department of Electrical Engineering and Electronics, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Overton</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>UK Health Security Agency, 10 South Colonnade, Poplar, London, UK; Department of Mathematical Sciences, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>UK Health Security Agency, 10 South Colonnade, Poplar, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">influenza-like-illness</Keyword><Keyword MajorTopicYN="N">syndromic surveillance</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39557283</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2024.107307</ArticleId><ArticleId IdType="pii">S1201-9712(24)00383-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle>